A Phase 4 interventional study of Benralizumab in In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India, sponsored by AstraZeneca. Completed at 13 sites in India. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-12-11.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.
Among the 39 studies testing benralizumab in Asthma, this one is the 19th largest by enrollment, is one of 3 that started in 2021, is one of 9 in phase 4, and was the 33rd registered.
4,849 studies on the registry are indexed under Asthma; 605 are open to participants now.
Browse Asthma studies →3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Austria and 11 more countries
Ages 6+
University of California, San Diego · Sites in United States
Ages 18–75
Endeavor Health · Sites in United States
Ages 18+
By country, each count listing its studies:
benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 139 is above the median of 79 across 3,344 interventional studies indexed under Asthma.
Median enrollment 128 across the 39 interventional studies. Of the 31 that completed or were terminated, 24 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 39 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
359 studies in Asthma by AstraZeneca: 19 open now, 28 under way, 8 of them phase 3. Of 330 finished, 129 (39%) have results posted.
Among the 359 studies in Asthma by AstraZeneca, this one is the 134th largest by enrollment of the 248 interventional ones that give a count, is one of 14 that started in 2021, is one of 23 in phase 4, and was the 286th registered.
AstraZeneca’s Asthma studies by the year they started, since 1996.
3 of the studies testing benralizumab in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692180Phase 3AstraZenecaA Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma | 2026-12-23 |
| NCT06385236University of California, San DiegoLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping | 2027-06-30 |
| NCT07654842Endeavor HealthFasenra: An Asthma Study | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 39 studies testing benralizumab in Asthma, from their registry updates:
Among AstraZeneca’s 359 in Asthma:
This tab as a report to print or save as PDF → With an account.
Benralizumab is a humanised, afucosylated, monoclonal antibody that binds specifically to the human interlukin-5 (IL-5) receptor alpha subunit (IL-5Rα) of target cells such as eosinophils and basophils (Takatsu et al, 1994; Toba et al, 1999; Pelaia et al, 2020).
Benralizumab was generally well tolerated by patients in clinical trials, with no apparent safety concerns.
This study shall be conducted at 10 centers across India. The primary outcome measures will be
Fasenra (benralizumab) has been recently approved in India with the condition to conduct a Phase 4 postmarketing study in the Indian population, as previous studies did not include patients from India. This prospective postmarketing safety study is planned to meet the regulatory mandate and assess the safety of benralizumab treatment in adult patients of severe asthma with eosinophilic phenotype over a period of 24 weeks. This interventional study will provide insights into the potential risks of eosinophil-lowering therapies when used in routine clinical care in India. The study will also evaluate the effectiveness of benralizumab in reducing asthma exacerbations.
This is a prospective, single-arm, multicentre, interventional, Phase 4 study investigating the safety, tolerability, and effectiveness of Fasenra (benralizumab) in adult patients of severe asthma with eosinophilic phenotype over a period of 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm, Phase-IV
Biological: Benralizumab
Prospective, Single-arm Study to Assess the Safety of Fasenra® (Benralizumab) in Adult Patients of Severe Asthma with Eosinophilic Phenotype in India
Participants With Adverse Events (AEs), Serious AEs, and Treatment-emergent AEs
The number and percentage of participants who experienced at least one adverse event (AE), serious AE, or treatment-emergent AE experienced are presented
Time frame: From study treatment to follow-up (up to 24 weeks)
Severity of AEs
Severity of adverse events (AEs) by intensity grade
Time frame: From study treatment to follow-up (up to 24 weeks)
Participants With AEs That Led to Study Treatment Discontinuations or Modifications
Participants with adverse events (AEs) that led to study treatment discontinuations or modifications
Time frame: From study treatment to follow-up (up to 24 weeks)
Time to First Asthma Exacerbation
Time to first asthma exacerbation in days in participants with asthma exacerbation
Time frame: From study treatment to follow-up (up to 24 weeks)
Exacerbation Rate: Before and After Treatment
The annual exacerbation rate for each participant was calculated by dividing the total number of exacerbations by the number of days participated in the study and multiplying by 365.
Time frame: From study treatment to follow-up (up to 24 weeks)
Annualized Exacerbation Rate: Overall
Overall annualized exacerbation rate. The annual exacerbation rate for each participant was calculated by dividing the total number of exacerbations by the number of days participated in the study and multiplying by 365.
Time frame: From study treatment to follow-up (up to 24 weeks)
Overall Investigators Assessment
Overall investigator's assessment on the outcome of the treatment: "well controlled", "partly controlled", and "uncontrolled."
Time frame: From study treatment to follow-up (up to 24 weeks)
Change in Blood Eosinophil Levels From Baseline at Weeks 4, 16, and 24
Mean change in blood eosinophil levels from baseline at Weeks 4, 16, and 24
Time frame: Baseline and Weeks 4, 16, and 24
| Milestone | Benralizumab |
|---|---|
| Started | 139 |
| Completed | 124 |
| Not completed | 15 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: One participant included in study but not included in analysis as did not meet eligibility criteria | 1 |
The number and percentage of participants who experienced at least one adverse event (AE), serious AE, or treatment-emergent AE experienced are presented
| Participants | Benralizumab |
|---|---|
| Participants with at least one AE (including SAEs) | 44 |
| Participants with at least one serious AE | 5 |
| Participants with at least one treatment-emergent AE (including SAEs) | 43 |
| Participants with at least one non-treatment-emergent and non-serious AE | 1 |
Severity of adverse events (AEs) by intensity grade
| Participants | Benralizumab |
|---|---|
| Participants with at least one mild AE | 33 |
| Participants with at least one moderate AE | 16 |
| Participants with at least one severe AE | 1 |
Participants with adverse events (AEs) that led to study treatment discontinuations or modifications
| Participants | Benralizumab |
|---|---|
| Participants With AEs That Led to Study Treatment Discontinuations or Modifications | 0 |
Time to first asthma exacerbation in days in participants with asthma exacerbation
| days | Benralizumab |
|---|---|
| Time to First Asthma Exacerbation | 112.6 ± 50.45 |
The annual exacerbation rate for each participant was calculated by dividing the total number of exacerbations by the number of days participated in the study and multiplying by 365.
| exacerbations events/year | Benralizumab |
|---|---|
| Exacerbation before study | 2.0 ± 0.00 |
| Exacerbation at end of study | 0.2 ± 0.47 |
Overall annualized exacerbation rate. The annual exacerbation rate for each participant was calculated by dividing the total number of exacerbations by the number of days participated in the study and multiplying by 365.
| exacerbation events/year | Benralizumab |
|---|---|
| Annualized Exacerbation Rate: Overall | 0.36 |
Overall investigator's assessment on the outcome of the treatment: "well controlled", "partly controlled", and "uncontrolled."
| Participants | Benralizumab |
|---|---|
| Well controlled | 83 (52.72 to 69.72) |
| Partly controlled | 45 (25.46 to 41.96) |
| Uncontrolled | 7 (2.11 to 10.39) |
Mean change in blood eosinophil levels from baseline at Weeks 4, 16, and 24
| cells/mm^3 | Benralizumab |
|---|---|
| Week 4 (Visit 2) | -511 ± 779.13 |
| Week 16 (Visit 4) | -546 ± 867.79 |
| Week 24 (Visit 5) | -541 ± 893.62 |
Collected over From screening to follow-up (up to 27 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benralizumab | 0/138 (0%) | 5/138 (3.6%) | 39/138 (28.3%) |
| Event | Benralizumab |
|---|---|
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 4/138 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 4/138 |
| PyrexiaGeneral disorders | 3/138 |
| H1n1 influenzaInfections and infestations | 1/138 |
| Back painMusculoskeletal and connective tissue disorders | 1/138 |
| ConstipationGastrointestinal disorders | 1/138 |
| Event | Benralizumab |
|---|---|
| PyrexiaGeneral disorders | 20/138 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/138 |
| NasopharyngitisInfections and infestations | 3/138 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 3/138 |
| HeadacheNervous system disorders | 2/138 |
| ParaesthesiaNervous system disorders | 2/138 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 2/138 |
| Productive coughRespiratory, thoracic and mediastinal disorders | 2/138 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 2/138 |
| AstheniaGeneral disorders | 2/138 |
| Age, Continuous(Years) | Benralizumab |
|---|---|
| Mean | 47.7 ± 14.3 |
| Sex: Female, Male(Participants) | Benralizumab |
|---|---|
| Female | 71 |
| Male | 67 |
| Race/Ethnicity, Customized(Participants) | Benralizumab |
|---|---|
| ASIAN | 138 |
| OTHER | 0 |
| Female, Indicate childbearing potential(Participants) | Benralizumab |
|---|---|
| Premenarchal | 0 |
| Premenopausal female | 6 |
| Postmenopausal female | 30 |
| Potentially able to bear children | 35 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2021 to primary completion in Jul 2023, 19 months.
Results were first posted in Dec 2024, 1 year 5 months after primary completion.
Of 66 industry-sponsored phase 4 interventional studies under Asthma, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's 19 months is close to that.
Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab